Momenta Pharmaceuticals (NASDAQ:MNTA) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.10, Morningstar.com reports. Momenta Pharmaceuticals had a negative net margin of 128.49% and a negative return on equity of 40.55%. The business had revenue of $14.88 million for the quarter, compared to analyst estimates of $16.99 million. During the same period in the previous year, the firm earned ($0.44) EPS. The business’s revenue for the quarter was down 38.2% compared to the same quarter last year.
Momenta Pharmaceuticals stock opened at $14.48 on Thursday. Momenta Pharmaceuticals has a 52 week low of $11.72 and a 52 week high of $32.20. The stock has a market capitalization of $1.13 billion, a P/E ratio of -12.07 and a beta of 2.34.
In other Momenta Pharmaceuticals news, CEO Craig A. Wheeler sold 1,773 shares of the company’s stock in a transaction dated Friday, August 10th. The shares were sold at an average price of $26.06, for a total value of $46,204.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Elizabeth Stoner sold 4,152 shares of the company’s stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $27.33, for a total transaction of $113,474.16. Following the completion of the transaction, the director now owns 33,791 shares in the company, valued at $923,508.03. The disclosure for this sale can be found here. Insiders sold a total of 9,356 shares of company stock worth $252,705 over the last quarter. Insiders own 4.80% of the company’s stock.
MNTA has been the topic of several recent research reports. Stifel Nicolaus reiterated a “buy” rating and issued a $40.00 price objective on shares of Momenta Pharmaceuticals in a research report on Wednesday, October 10th. BidaskClub lowered shares of Momenta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 4th. ValuEngine lowered shares of Momenta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 16th. Zacks Investment Research upgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a research report on Monday, October 15th. Finally, Cantor Fitzgerald set a $24.00 price objective on shares of Momenta Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, October 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $27.00.
ILLEGAL ACTIVITY WARNING: “Momenta Pharmaceuticals (MNTA) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS” was posted by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.wkrb13.com/2018/11/08/momenta-pharmaceuticals-mnta-posts-quarterly-earnings-results-beats-expectations-by-0-10-eps.html.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.